共 15 条
Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure - Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
被引:192
作者:
Mark, Daniel B.
Nelson, Charlotte L.
Anstrom, Kevin J.
Al-Khatib, Sana M.
Tsiatis, Anastasios A.
Cowper, Patricia A.
Clapp-Channing, Nancy E.
Davidson-Ray, Linda
Poole, Jeanne E.
Johnson, George
Anderson, Jill
Lee, Kerry L.
Bardy, Gust H.
机构:
[1] Duke Clin Res Inst, Outcomes Res Grp, Durham, NC 27715 USA
[2] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA
[3] N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA
[4] Seattle Inst Cardiac Res, Seattle, WA USA
[5] Univ Washington, Med Ctr, Seattle, WA 98195 USA
关键词:
amiodarone;
defibrillators;
implantable;
heart failure;
congestive;
quality-adjusted life years;
cost-benefit analysis;
D O I:
10.1161/CIRCULATIONAHA.105.581884
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background - In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), implantable cardioverter-defibrillator (ICD) therapy significantly reduced all-cause mortality rates compared with medical therapy alone in patients with stable, moderately symptomatic heart failure, whereas amiodarone had no benefit on mortality rates. We examined long-term economic implications of these results. Methods and Results - Medical costs were estimated by using hospital billing data and the Medicare Fee Schedule. Our base case cost-effectiveness analysis used empirical clinical and cost data to estimate the lifetime incremental cost of saving an extra life-year with ICD therapy relative to medical therapy alone. At 5 years, the amiodarone arm had a survival rate equivalent to that of the placebo arm and higher costs than the placebo arm. For ICD relative to medical therapy alone, the base case lifetime cost-effectiveness and cost-utility ratios (discounted at 3%) were $38 389 per life-year saved (LYS) and $41 530 per quality-adjusted LYS, respectively. A cost-effectiveness ratio <$100 000 was obtained in 99% of 1000 bootstrap repetitions. The cost-effectiveness ratio was sensitive to the amount of extrapolation beyond the empirical 5-year trial data: $127 503 per LYS at 5 years, $88 657 per LYS at 8 years, and $58 510 per LYS at 12 years. Because of a significant interaction between ICD treatment and New York Heart Association class, the cost-effectiveness ratio was $29 872 per LYS for class II, whereas there was incremental cost but no incremental benefit in class III. Conclusions - Prophylactic use of single-lead, shock-only ICD therapy is economically attractive in patients with stable, moderately symptomatic heart failure with an ejection fraction <= 35%, particularly those in NYHA class II, as long as the benefits of ICD therapy observed in the SCD- HeFT persist for at least 8 years.
引用
收藏
页码:135 / 142
页数:8
相关论文